Docetaxel and epirubicin salvage regimen in relapsed anthracycline- sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Our aim in this paper is to verify the efficacy and safety of a epirubicin and docetaxel salvage regimen for anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy. Thirty-two metastatic breast cancer patients were treated with epirubicin and docetaxel every 21 days. Of the 31 evaluable patients, there were 13/31 (41.9%) partial responses and no complete responses. Median time to progression was 12 months (95% CI, 4-60 months) and median survival duration was 41 months (95% CI, 1.2-80.8 months). According to the Cox model, ECOG performance and response group were statistically significant variables, and visceral metastasis was a borderline significant variable with regards to overall survival. Although this salvage regimen showed a high rate of hematologic toxicities, it was a relatively active regimen with manageable toxicities and no cardiac dysfunction. We propose that this salvage regimen could be carefully used in anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy.

Original languageEnglish
Pages (from-to)67-73
Number of pages7
JournalInvestigational New Drugs
Volume27
Issue number1
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

docetaxel
Epirubicin
Anthracyclines
Breast Neoplasms
Survival
Therapeutics
Proportional Hazards Models
Neoplasm Metastasis
Safety

Keywords

  • Anthracycline
  • Docetaxel
  • Epirubicin
  • Metastatic breast cancer
  • Sensitive

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

@article{f2036bf0166748fc94970701c664170a,
title = "Docetaxel and epirubicin salvage regimen in relapsed anthracycline- sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy",
abstract = "Our aim in this paper is to verify the efficacy and safety of a epirubicin and docetaxel salvage regimen for anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy. Thirty-two metastatic breast cancer patients were treated with epirubicin and docetaxel every 21 days. Of the 31 evaluable patients, there were 13/31 (41.9{\%}) partial responses and no complete responses. Median time to progression was 12 months (95{\%} CI, 4-60 months) and median survival duration was 41 months (95{\%} CI, 1.2-80.8 months). According to the Cox model, ECOG performance and response group were statistically significant variables, and visceral metastasis was a borderline significant variable with regards to overall survival. Although this salvage regimen showed a high rate of hematologic toxicities, it was a relatively active regimen with manageable toxicities and no cardiac dysfunction. We propose that this salvage regimen could be carefully used in anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy.",
keywords = "Anthracycline, Docetaxel, Epirubicin, Metastatic breast cancer, Sensitive",
author = "Seo, {Jae Hong} and Sung, {Hwa Jung} and Park, {Kyong Hwa} and Choi, {In Keun} and Oh, {Sang Cheul} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk} and Aeree Kim and Lee, {Jae Bok} and Koo, {Bum Hwan}",
year = "2009",
month = "2",
day = "1",
doi = "10.1007/s10637-008-9151-2",
language = "English",
volume = "27",
pages = "67--73",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Docetaxel and epirubicin salvage regimen in relapsed anthracycline- sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy

AU - Seo, Jae Hong

AU - Sung, Hwa Jung

AU - Park, Kyong Hwa

AU - Choi, In Keun

AU - Oh, Sang Cheul

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

AU - Kim, Aeree

AU - Lee, Jae Bok

AU - Koo, Bum Hwan

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Our aim in this paper is to verify the efficacy and safety of a epirubicin and docetaxel salvage regimen for anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy. Thirty-two metastatic breast cancer patients were treated with epirubicin and docetaxel every 21 days. Of the 31 evaluable patients, there were 13/31 (41.9%) partial responses and no complete responses. Median time to progression was 12 months (95% CI, 4-60 months) and median survival duration was 41 months (95% CI, 1.2-80.8 months). According to the Cox model, ECOG performance and response group were statistically significant variables, and visceral metastasis was a borderline significant variable with regards to overall survival. Although this salvage regimen showed a high rate of hematologic toxicities, it was a relatively active regimen with manageable toxicities and no cardiac dysfunction. We propose that this salvage regimen could be carefully used in anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy.

AB - Our aim in this paper is to verify the efficacy and safety of a epirubicin and docetaxel salvage regimen for anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy. Thirty-two metastatic breast cancer patients were treated with epirubicin and docetaxel every 21 days. Of the 31 evaluable patients, there were 13/31 (41.9%) partial responses and no complete responses. Median time to progression was 12 months (95% CI, 4-60 months) and median survival duration was 41 months (95% CI, 1.2-80.8 months). According to the Cox model, ECOG performance and response group were statistically significant variables, and visceral metastasis was a borderline significant variable with regards to overall survival. Although this salvage regimen showed a high rate of hematologic toxicities, it was a relatively active regimen with manageable toxicities and no cardiac dysfunction. We propose that this salvage regimen could be carefully used in anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy.

KW - Anthracycline

KW - Docetaxel

KW - Epirubicin

KW - Metastatic breast cancer

KW - Sensitive

UR - http://www.scopus.com/inward/record.url?scp=62749130644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62749130644&partnerID=8YFLogxK

U2 - 10.1007/s10637-008-9151-2

DO - 10.1007/s10637-008-9151-2

M3 - Article

C2 - 18758689

AN - SCOPUS:62749130644

VL - 27

SP - 67

EP - 73

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -